Interpace Biosciences Inc (IDXG)
1.48
+0.10
(+7.25%)
USD |
OTCM |
May 24, 16:00
Interpace Biosciences Enterprise Value: 12.51M for May 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 24, 2024 | 12.51M |
| May 23, 2024 | 12.07M |
| May 22, 2024 | 12.33M |
| May 21, 2024 | 12.68M |
| May 20, 2024 | 12.02M |
| May 17, 2024 | 12.02M |
| May 16, 2024 | 12.36M |
| May 15, 2024 | 12.29M |
| May 14, 2024 | 12.37M |
| May 13, 2024 | 12.37M |
| May 10, 2024 | 12.37M |
| May 09, 2024 | 12.16M |
| May 08, 2024 | 12.02M |
| May 07, 2024 | 11.94M |
| May 06, 2024 | 11.98M |
| May 03, 2024 | 12.20M |
| May 02, 2024 | 12.20M |
| May 01, 2024 | 11.98M |
| April 30, 2024 | 12.24M |
| April 29, 2024 | 12.11M |
| April 26, 2024 | 12.59M |
| April 25, 2024 | 12.25M |
| April 24, 2024 | 12.82M |
| April 23, 2024 | 12.45M |
| April 22, 2024 | 12.37M |
| Date | Value |
|---|---|
| April 19, 2024 | 12.37M |
| April 18, 2024 | 12.46M |
| April 17, 2024 | 12.46M |
| April 16, 2024 | 12.46M |
| April 15, 2024 | 12.46M |
| April 12, 2024 | 12.09M |
| April 11, 2024 | 11.94M |
| April 10, 2024 | 12.51M |
| April 09, 2024 | 12.55M |
| April 08, 2024 | 12.37M |
| April 05, 2024 | 12.37M |
| April 04, 2024 | 12.68M |
| April 03, 2024 | 12.59M |
| April 02, 2024 | 12.59M |
| April 01, 2024 | 12.05M |
| March 31, 2024 | 12.59M |
| March 28, 2024 | 12.41M |
| March 27, 2024 | 12.65M |
| March 26, 2024 | 12.85M |
| March 25, 2024 | 12.93M |
| March 22, 2024 | 12.93M |
| March 21, 2024 | 12.85M |
| March 20, 2024 | 13.02M |
| March 19, 2024 | 12.41M |
| March 18, 2024 | 12.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-0.2421M
Minimum
Sep 04 2020
69.06M
Maximum
Feb 21 2020
21.49M
Average
17.00M
Median
Jul 14 2023
Enterprise Value Benchmarks
| Fonar Corp | 36.31M |
| XWELL Inc | -3.924M |
| ProPhase Labs Inc | 107.79M |
| Applied DNA Sciences Inc | -1.317M |
| Veracyte Inc | 1.381B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.468M |
| Revenue (Quarterly) | 10.27M |
| Total Expenses (Quarterly) | 9.399M |
| EPS Diluted (Quarterly) | 0.11 |
| Gross Profit Margin (Quarterly) | 59.10% |
| Profit Margin (Quarterly) | 4.56% |
| Earnings Yield | 29.05% |
| Operating Earnings Yield | 57.49% |
| Normalized Earnings Yield | 33.89 |